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ABSTRACT
Objectives: Metformin is an established first-
line treatment for type 2 diabetes mellitus
(T2DM) patients but intensification of oral
anti-diabetic therapy is usually required over
time. The effectiveness of diabetes control with
vildaGliptin and vildagliptin/mEtformin
(EDGE) study compared effectiveness and
safety of vildagliptin and other oral anti-
diabetic drugs (OAD) in 45,868 patients
worldwide with inadequately controlled T2DM
by monotherapy under real-life conditions.
Here, we present effectiveness results for
patients receiving vildagliptin (vildagliptin
cohort) or another OAD (comparator cohort)
add-on to monotherapy in Bulgaria.
Methods: The eligible diabetes patients
inadequately controlled with current
monotherapy were assigned to add-on
treatment, which was chosen by the physician
based on patient’s need. Effectiveness was
assessed by glycated hemoglobin (HbA1c) drop
and by means of a composite endpoint assessing
the proportion of patients responding to
treatment (HbA1c \7%) without proven
hypoglycemic event and significant weight
gain ([5%) after 12 months of treatment.
Results: In total, 754 patients were enrolled in
Bulgaria, 384 in the vildagliptin cohort and 369
in the comparator cohort. Mean HbA1c change
from baseline was significantly higher with
vildagliptin compared to the comparator
(-1.35% in the vildagliptin cohort and -0.55%
in the comparator cohort, P\0.001). In the
vildagliptin cohort, a higher proportion of
patients reached the composite endpoint
(HbA1c \7%, no hypoglycemic events, no
weight gain) when compared to the
comparator cohort (vildagliptin: 32.3%;
comparator: 8.4%; P\0.001). Overall,
vildagliptin was well tolerated with similarly
low incidences of total adverse events (3.4%
versus 1.9% in the comparator group) and
serious adverse events (2.3% versus 1.1% in the
comparator group).
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Conclusions: In real-life clinical practice in
Bulgaria, vildagliptin is associated with a
greater HbA1c drop, and a higher proportion
of patients reaching target HbA1c without
hypoglycemia and weight gain compared to
comparator.
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INTRODUCTION
Almost half of patients with type 2 diabetes
mellitus (T2DM) do not achieve globally
recognized blood glucose targets [1, 2]. It is
difficult to understand the reasons for this,
considering that during last decades the
armamentarium of resources to treat T2DM
has significantly increased. The reasons can be
sought in two main directions.
The first trend observed is the dramatic
increase in global prevalence of this disease
according to the International Diabetes
Federation. Currently, the prevalence in the
age group 20–79 years is 8.3% (382 million
people worldwide), but it is expected to rise
with 55% to a prevalence of 10.1% (592 million)
by 2035 [3]. For Bulgaria, the number of
patients with T2DM in 2013 was 427,000
people in the age group 20–79 years (7.6%)
according to the same source. It is expected the
prevalence of diabetes in Bulgaria will follow
the global trends. The enormous financial
resources destined to the treatment of diabetic
complications are constantly increasing
requiring identification of new therapeutic
approaches to delay complications in time.
The second trend observed is the
medications available for T2DM, until
recently, do not completely address all main
pathogenic mechanisms of the disease. It is well
known that T2DM is a chronic disease that
results from a combination of insulin resistance
and insulin deficiency caused by beta-cell
dysfunction [4]. The progressive nature of the
disease requires effective glycemic control to
reduce the risk of long-term micro- and
macrovascular complications related to
dysglycemia [5]. Metformin is the most widely
used oral anti-diabetic drug (OAD) and is
recommended as first-line therapy for patients
with T2DM [5]. However, as glycemic control
deteriorates, patients with T2DM usually
require more than one antidiabetic agent to
achieve glycemic targets [6–8]. Sulfonylureas
(SUs) are one of the most commonly used
second-line treatment options of T2DM [5] in
clinical practice usually in combination with
metformin [9]. SUs are commonly associated
with weight gain and hypoglycemia [5, 10]. In
patients with T2DM receiving OADs, both
weight gain and hypoglycemia are
independently associated with lower treatment
satisfaction and lower health-related quality of
life [11]. These adverse events are a well-
recognized reason for poor adherence to
chronic therapy, which finally results in
impaired disease control [12–14].
The new therapeutic classes such as incretin-
based therapies could be a solution for some of
the problems faced in treatment of T2DM, such
as improvement of glycemic control for longer
periods, limitation of glycemic fluctuations,
hypoglycemia, and weight gain. Long-term
effectiveness and safety trials are ongoing to
investigate the potential of their new mode of
action to overcome the burden of diabetes, to
improve diabetes control and to eliminate long-
term complications, with special focus on
cardiovascular outcomes [15].
International guidelines [5, 16] for the
treatment of T2DM underwent several
modifications in the last decade due to the fast
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dynamics of the understanding of the disease
pathogenesis and the introduction of
corresponding new medicines. This was based
on numerous randomized controlled clinical
trials (RCT), including ACCORD [17],
ADVANCE [18], VADT [19], that were
conducted and provided arguments of highest
level for the evidence-based medicine. Despite
RCTs high informative value, these studies have
often been blamed for lack of generalizability of
their findings because of the precisely enrolled
subjects, better therapy compliance, medicines
variations and strictly regulated dose regimen.
After all, this is not the usual population, and it
receives a strictly pre-determined treatment,
beyond the usual practice. For all these, RCTs
do not correspond to the routine practice and
therefore a new type of pragmatic trial needs to
be conducted in real-life settings, which will not
replace RCTs, but will rather provide additional
information and will help build a uniform
concept of the treatment of diabetes mellitus
[18, 20–22]. The number of these real-life
clinical trials is still too small.
As mentioned above, metformin is used as a
therapy of choice for the treatment of T2DM,
irrespective of patient’s body weight, when
adequate results cannot be achieved by diet
and physical activity alone [5, 16]. The latest
clinical recommendations of the American
Diabetes Association (ADA) and the European
Association for the Study of Diabetes (EASD)
from 2012 [5], and of the American Association
of Clinical Endocrinologists (AACE) from 2013
[16] suggest that the choice of a second agent to
be added in case of inadequate efficiency of
metformin monotherapy is based on individual
judgment. It is important to underline that in
these key strategic papers, the incretin-based
therapy is constantly gaining positions, with
the tendency to become second-line therapy
added on the top of metformin.
A recent meta-analysis conducted to assess
the efficacy and safety of all available second-
line antihyperglycemic therapies in patients
with T2DM inadequately controlled by
metformin monotherapy revealed that
dipeptidyl peptidase-4 (DPP-4) inhibitors are as
effective as the other therapeutic classes in
improvement of glycemic control, but with
modest benefits with respect to weight gain
and overall hypoglycemia [23].
Maintaining good glycemic control is
essential for risk reduction of micro- and
macrovascular complications associated with
diabetes [24]. DPP-4 inhibitors possess a
number of pharmacological attributes that
would suggest cardiovascular safety. In
addition to glucose lowering and weight
neutrality, they lower blood pressure, improve
postprandial hyperlipidaemia, reduce
inflammatory markers, diminish oxidative
stress, and improve endothelial function [25].
However, large-scale clinical trials, including
studies from routine clinical practice, are also
needed to identify benefits or harms from this
therapy in a real-life setting. Such a study is the
multinational study entitled effectiveness of
diabetes control with vildaGliptin and
vildagliptin/mEtformin (EDGE) with protocol
number CLAF237A2404 [26].
Cardiovascular disease (CVD) is a major
cause of morbidity and mortality for
individuals with diabetes and the largest
contributor to the direct and indirect costs of
diabetes. The common conditions coexisting
with type 2 diabetes (e.g., hypertension and
dyslipidemia) are clear risk factors for CVD, and
diabetes itself confers independent risk [27].
Bulgaria has one of the highest rates of
premature death from cardiovascular disease in
Europe [28] and despite clear recommendations
in current guidelines for the treatment of T2DM
(5, 16), ineffective monotherapy regimens
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remain high with many patients not receiving
timely therapy intensification and
consequently suffering with insufficient
glycemic control [29]. The proportion of
patients treated with novel therapeutic drug
classes including DPP-4 inhibitors is relatively
low. There is also an absence of depth analysis
of the therapeutic behavior of physicians
treating T2DM in Bulgaria and studies
identifying the major problems facing in
routine clinical practice. The aim of this sub-
analysis was to assess effectiveness and
tolerability of second-line vildagliptin
combinations versus other OAD two-agent
combinations for patients enrolled in Bulgaria.
METHODS
Study Design
The EDGE was a 1-year, multinational,
multicenter, post-authorization, prospective,
observational study conducted in 45,868
subjects at 2,957 sites in 27 countries, grouped
into 5 regions in which vildagliptin is approved:
East Asia, Europe, Latin America, Near East, and
India. Of those, 754 patients were enrolled from
24 sites in Bulgaria. The study included patients
aged over 18 years, with T2DM and inadequate
glycemic control while receiving OAD
monotherapy with metformin, a SU,
a-glucosidase inhibitor (AGI) or
thiazolidinedione (TZD) and for whom, at the
physician’s discretion a second OAD was
considered. The physician could institute any
medicine he/she might deem appropriate,
except an incretin-based therapy [DPP-4
inhibitors/glucagon-like peptide-1 (GLP-1)
agonists] other than vildagliptin. Patients who
were planned to initiate a DPP-4 inhibitor other
than vildagliptin, or an incretin mimetic/
analog, or who required three or more OADs
at study entry were excluded. Patients who were
using insulin at the time of study entry and
patients with a history of hypersensitivity to
any of the study drugs or drugs of similar
chemical classes were also excluded.
Patients were assigned by their physician to
one of the following two groups: vildagliptin
group (vildagliptin 50 mg twice daily add-on as
second OADs or vildagliptin/metformin 50 mg/
850 or 1,000 mg twice daily) or comparator
group (add-on second OADs—SU, metformin,
TZD, meglitinides, AGI to the ineffective
monotherapy).
The present sub-analysis does not contain
any new studies with human or animal subjects
performed by any of the authors.
Data Collection
During the first routine visit the following
patient baseline (BL) data were collected: age,
gender, race, ethnicity, body weight, medical
history, T2DM duration, T2DM therapy prior to
study entry, newly initiated add-on OAD
(second component of index medication),
other medications (by class), most recent
HbA1c test date and result, other laboratory
tests. To estimate the glomerular filtration rate
(GFR) by the modification of diet in renal
disease (MDRD) method, creatinine data were
collected. After 12 months, the final data
collected included body weight, changes of
index medication, most recent HbA1c test data
and result, other laboratory test dates and
results, adverse events (AEs) and serious AEs
(SAEs) and study completion status.
Evaluation Criteria in EDGE Study
The primary effectiveness endpoint (PEP) was
defined as the proportion of patients having a
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treatment response (HbA1c reduction from BL
to Month 12 endpoint [0.3%) and no
tolerability issues [peripheral edema, proven
hypoglycemic event, discontinuation due to a
gastrointestinal (GI) event, or weight gain C5%)
[30]. As described in the primary manuscript
regarding EDGE study results [26], this
composite endpoint was chosen on the basis
of the balanced decisions that clinicians need to
make when choosing a glucose-lowering agent,
namely the combination of efficacy [as defined
by European Medicines Agency (EMA) and the
Food and Drug Administration (FDA)] and most
common side effects. For more details, please
refer to original article [26].
Patients who could not be categorized as a
success or failure (e.g., due to missing HbA1c or
body weight data at 12-month endpoint) were
considered non-evaluable. Non-evaluable
patient data were considered failures in
calculation of the odds ratio (OR) for success.
The main analysis of the PEP utilized the per
protocol (PP) population; data were censored if
patient changed index therapy. Hypoglycemia
was defined as symptoms suggestive of
hypoglycemia that resolved promptly on the
administration of oral carbohydrate (including
mild and severe events). The most important
endpoint from clinical perspective was the
secondary effectiveness endpoints (SEP),
defined as the proportion of patients with BL
HbA1c C7% that achieved target HbA1c \7.0%
after 12 months, without weight gain C3% or
confirmed hypoglycemic episodes in subjects
with baseline HbA1c C7%.
The secondary safety endpoints were
determination of the time to death, SAE or AE
occurring in the vildagliptin group
[vildagliptin/metformin (fixed combinations)]
versus the comparator group in real clinical
practice settings; interruption of the treatment
assigned due to a SAE; interruption of the
treatment assigned due to an AE; interruption
of the treatment assigned due to any cause
other than SAE/AE; assessment of the effect of
adding vildagliptin or vildagliptin/metformin
(fixed combination) on the individual
tolerability factors (body weight, peripheral
edema, confirmed hypoglycemic episodes, and
GI events) compared to the reference group in
which another OAD is added.
Safety was assessed by AE reporting and
measurement of specific laboratory values.
Specific attention was given to hepatic safety
due to a requirement for liver function
monitoring prior and during treatment with
vildagliptin [31].
All these combined endpoints were defined
in agreement with the European Medicines
Agency when this study was designed.
Statistical Analysis
This post hoc analysis provides mainly
descriptive statistics. Inference is provided for
primary and secondary endpoints. For these,
the probability of success was analyzed using a
binary logistic regression model to calculate
ORs with 95% confidence intervals (CIs). The
OR expresses odds in favor of success with
vildagliptin or vildagliptin/metformin relative
to odds in favor of success with comparator
OADs. All statistical evaluations were performed
using SAS software, version 9.3 (SAS Institute
Inc., Cary, North Carolina, USA. For more
details please refer to the original article [26].
In this post hoc analysis only the unadjusted
OR is provided.
RESULTS
In total 754 patients were enrolled in Bulgaria,
384 in the vildagliptin cohort and 369 in the
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comparator cohort. One patient in the
vildagliptin cohort was excluded due to
inadequate source documentation or problems
with quality/accuracy of data entry (Table 1).
The intention-to-treat (ITT) population, used
for baseline demographics and safety analyses,
comprised 384 and 369 patients receiving dual
therapy with newly prescribed vildagliptin or a
non-vildagliptin OAD added to prior
monotherapy, respectively.
The PP population was a subset of the ITT
population used for the analyses of effectiveness
endpoints and comprised 384 patients in the
vildagliptin, and 369 in the comparator cohort.
Table 2 summarizes BL characteristics of the
ITT population. Mean age of participants was
58.8 ± 9.5 years. Mean BMI was 31.9 ± 5.0
kg/m2 and mean HbA1c was comparable
(vildagliptin: 8.5%; comparator: 8.2%). Mean
duration of diabetes was 5.8 ± 4.8 years.
Patient populations and flow is presented in
Table 1. Additional risk factors are presented in
Table 3.
Table 4 reports index therapies in the ITT
population by cohort. According to distribution
by therapy of patients in both groups the
majority of subjects in the reference group
were on combination of metformin plus SU
(90.8%), the second OAD added was AGI or TZD
in 9% of subjects. In the vildagliptin group,
majority of patients were on vildagliptin plus
metformin (77.6%) combination, the rest of
subjects (22.4%) were on vildagliptin plus SU
combination.
PEPs and SEPs
Figure 1 shows proportions of patients
achieving the PEP—HbA1c reduction [0.3%,
without any tolerability issues: peripheral
edema, confirmed hypoglycemia, interruption
due to GI reactions, and significant weight gain
[5%. The proportion of subjects successfully
achieving this goal was 72.9% in the
vildagliptin group versus 40.1% in the
comparator group (P\0.0001), resulting in an
unadjusted OR 4.02 [95% CI 2.96–5.46].
After 12 months of treatment, unadjusted
HbA1c decreased in both cohorts (vildagliptin
cohort -1.35%, comparator cohort -0.55%) (see
Table 5). The drop was significantly greater with
vildagliptin compared to comparator (P\0.001)
(analysis not pre-specified in protocol).
A higher proportion of patients, in the
vildagliptin cohort, reached the secondary
composite endpoint (HbA1c \7%, no
hypoglycemic events, no weight gain) when
compared to the comparator cohort
(vildagliptin 32.3%, comparator 8.4%;
P\0.0001) resulting in an unadjusted odds
ratio 5.2 (95% CI 3.35–8.17) (Fig. 2). The
results regarding primary and secondary
efficacy and tolerability endpoints are
summarized in Table 6.
Safety
The incidence of AEs was comparable between
vildagliptin and comparator cohorts. Table 7
summarizes AEs and SAEs that occurred during
study, listed by system organ classes (SOC). In
the vildagliptin group, the incidence of AEs was
13 (3. 4%) versus 7 (1.9%) in the comparator
group. The SAEs reported were 9 (2.3%) and 4
(1.1%) in the vildagliptin and comparator
groups, respectively. Only one hypoglycemic
event was reported in the comparator group
(use of metformin and SU).
DISCUSSION
The results of the presented sub-analysis of the
EDGE study confirmed effectiveness and
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tolerability of vildagliptin used as a second-line
OADs therapy in routine clinical settings in
Bulgaria. In the Bulgarian population included
in the EDGE study, the mean HbA1c drop from
baseline was significantly higher with
vildagliptin compared to the comparators
(-1.35% in the vildagliptin cohort and
-0.55% in the comparator cohort, P\0.001).
In the vildagliptin cohort, a higher proportion
of patients reached the PEPs [72.9% in the
vildagliptin group versus 40.1% in the
comparator group (P\0.0001)]. Current
guidelines recommend that T2DM treatment
should achieve target HbA1c level of \7%
without increasing the risk of hypoglycemia,
weight gain, and worsening cardiovascular
prognosis [5, 32]. Almost four times more
patients in the vildagliptin cohort reached the
composite endpoint (HbA1c \7%, no
hypoglycemic events, no weight gain) when
compared to the comparator cohort
(vildagliptin: 32.3%; comparator: 8.4%;
P\0.001). Overall, vildagliptin was well
tolerated with similarly low incidences of total
adverse events (3.4% versus 1.9% in the
comparator group) and serious adverse events






Vildagliptin cohort Comparator cohort
Assigned to 385 369
No adequate source documentation at site;
lack of quality and accuracy of data entry
1 0
ITTb 384 369
Patients completed 371 352
Patients discontinued 13 17
Protocol deviations 0 2
Per protocolc 384 369
a The enrolled population includes all patients who gave documented informed consent
b The intent-to-treat (ITT) population is a subset of the enrolled population and includes all patients who were assigned to
new treatment at study start. Sites and/or patients identiﬁed with quality and compliance ﬁndings, irregular data were
excluded from the ITT analysis population
c The per protocol (PP) population is a subset of the ITT population. The PP population was used for the analyses of
effectiveness endpoints. Patients with the following deviations at baseline assessment were excluded from the per protocol
population: patients receiving dipeptidyl peptidase-4 (DPP-4) inhibitors at baseline or within 1 month prior to baseline;
patients receiving glucagon-like peptide-1 (GLP-1) mimetics/analogs at baseline or within 1 month prior to baseline;
patients receiving insulin at baseline; patients receiving only newly initiated monotherapy or more than two oral anti-
diabetic medications at baseline; drug-naive patients at baseline (patients not taking any diabetic medication prior to
baseline); patients who swapped from one oral anti-diabetic medication or class to another at baseline; patients receiving
investigational drug at baseline or 30 days prior to baseline or 5 half-lives prior to baseline; patients receiving more than one
oral anti-diabetic medication prior to baseline
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(2.3% versus 1.1% in the comparator group). The
presented data regarding vildagliptin
effectiveness assessed in routine clinical
practice are consistent with the results from
RCTs conducted until now where vildagliptin
was used as an agent for oral mono- and
combined therapy with other hypoglycemic
agents for the treatment of T2DM [33–42].
Overall the present safety and tolerability
findings in this sub-analysis of the EDGE study
are in line with RCTs of vildagliptin showing no
safety signals related to cardio- or
cerebrovascular (CCV), pancreatitis, hepatic,
immune system or skin-related disorders [33–36].
Maintaining good glycemic control without
increasing the risk of CV events is essential
requirement for type 2 diabetes therapy
nowadays [24, 43]. The presented results
regarding overall CV safety are in line with the
large meta-analysis showing that vildagliptin
was not associated with an increased risk of
adjudicated CCV events relative to all
comparators in the broad population of type 2
diabetes including patients at increased risk of
CCV events [34]. A recently published meta-
analysis revealed that DPP-4 inhibitors should
be considered to have a neutral effect on CV
outcomes [44]. Treatment with DPP-4 inhibitors
Table 3 Additional Risk factors
Baseline risk factors
Risk factors Vildagliptin (n 5 384) (%) Comparator (n 5 369) (%) Total (n5 753) (%)
Hypertension 206 (53.7) 182 (49.3) 388 (51.5)
Lipid disorders 85 (22.1) 61 (16.5) 146 (19.4)
Macrovascular complications 37 (9.6) 39 (10.6) 76 (10.1)
Microvascular complications 79 (20.6) 63 (17.1) 142 (18.9)
Data presented as n (%)
Table 2 Demographic and patient baseline characteristics (ITT Population)
Baseline characteristics
Characteristic Vildagliptin Comparator Total
N 384 369 753
Age (years) 56.5 ± 8.9 61.2 ± 9.6 58.8 ± 9.5
Gender
Male 192 (50.0%) 177 (48.0%) 369 (49.0%)
Female 192 (50.0%) 192 (52.0%) 384 (51.0%)
BMI (kg/m2) 32.8 ± 5.5 31 ± 4.4 31.9 ± 5.0
Baseline HbA1c (%) 8.5 ± 1.4 8.2 ± 1.1 8.3 ± 1.3
Duration of T2DM (years) 5.2 ± 4.2 6.4 ± 5.3 5.8 ± 4.8
Data presented as mean± or n (%)
BMI body mass index, HbA1c glycated hemoglobin, T2DM type 2 diabetes mellitus
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compared with placebo shows no increase in
risk with regards to all-cause mortality, CV
mortality, acute coronary syndrome, or stroke
[44]. It is yet to be seen if the results of the still
ongoing large-scale cardiac outcome trials will
change the current knowledge about DPP-4
inhibitors CV effects [45, 46].
The large-scale studies conducted in the
recent years (ACCORD, ADVANCE and VADT)
[17–19] have dramatically changed the
therapeutic paradigm, going beyond the One-
Glycemic-Goal-for-All concept, and showing
the need to use an individualized approach in
the therapy. Suboptimal glycemic control is
evidenced by a number of population statistic
studies on diabetes control [47], some of them
conducted in Bulgaria [48]. These studies raise
disputes on whether or not randomized
controlled trials are a real reflection of routine
clinical practice highlighting the need for real-
life studies. It is in such studies where the actual
effectiveness of a drug can be evaluated, which
is different than its efficacy. Although used as
synonyms in most cases, these two terms are
different. Efficacy can be defined as the effect in
ideal circumstances (RCTs). Effectiveness can be
the effect in usual circumstances (real-life
studies) [49]. Both RCTs and real-life studies
have restrictions and should be regarded as
complementing each other [50]. There is a need
to know both strong and weak points of each
study type. Physician’s leading decision, lack of
randomization, centralized laboratory, active
monitoring, etc., are among the weaknesses of
the real-life studies [50].
Regardless all the potential design
weaknesses, one of the biggest merits of EDGE
study could be seen in the confirmation of
insufficient glycemic control worldwide, despite
all strong recommendations for potential
benefits of the achievement of the glycemic
targets in type 2 diabetes [26].
The presented sub-analysis regarding
Bulgarian results from EDGE study confirmed
the insufficient glycemic control too. Many
factors may contribute to that suboptimal
glucose control. According to the baseline
characteristics of the enrolled patients, we
could conclude that Bulgarian physicians
decide to add second OADs at HbA1c level
Table 4 Index medication (ITT population)
Treatments Comparator cohort (n5 369)
n patients (%)




Alpha GIs–metformin 11 (3.0) 0 (0.0) 11 (1.5)
Alpha GIs–SUs 7 (1.9) 0 (0.0) 7 (0.9)
Glinides–metformin 2 (0.5) 0 (0.0) 2 (0.3)
Metformin–SUs 335 (90.8) 0 (0.0) 335 (44.5)
Metformin–TZDs 13 (3.5) 0 (0.0) 13 (1.7)
Metformin–vildagliptin 0 (0.0) 298 (77.6) 298 (39.6)
SUs–TZDs 1 (0.3) 0 (0.0) 1 (0.1)
SUs–vildagliptin 0 (0.0) 86 (22.4) 86 (11.4)
369 (100.0) 384 (100.0) 753 (100.0)
Data presented as n (%)
GI glucosidase inhibitors, SUs sulfonylureas, TZDs thiazolidinediones
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[8% (mean HbA1c was 8.3% ± 1.3). The
delayed treatment intensification could have a
harmful impact, as patients are very often left
on monotherapy for too long, even if they have
poor glycemic control and accumulate
complications (mean disease duration was
5.8 ± 4.8 years, mean HbA1c was 8.3% ± 1.3,
mean incidence of microvascular complication
was 18.9% and the prevalence of underlying
comorbidities as hypertension and lipid
disorders was 51.1% and 19.4%, respectively).
According to the study design, patient
disposition in treatment cohorts was totally
based on physician discretion. In the final
analysis of the EDGE trial, globally 28,442
patients in the vildagliptin group, and 15,349
patients in the reference group were included
[26]. This ratio of almost 2:1 is quite different
than the ratio in the Bulgarian population,
which is approximately 1:1 (384 in the
vildagliptin group and 369 in the comparator
group). The preferred second-line OADs were
SUs (90.8% of patients in the comparator cohort
were on combined therapy with metformin and
SU). According to the choice where to assign
their patients we could conclude that Bulgarian
physicians have a rather conservative attitude
towards the new drugs compared to their
colleagues worldwide.
The delayed and conservative approach in
treatment intensification is an example of
physician barriers that must be overcome
before the optimal glycemic control can be
obtained [51, 52]. These barriers are often
referred to ‘‘clinical inertia’’ or ‘‘benign
neglect’’ which describe recognition of the
problem but failure to act upon it [50, 51].
Other barriers linked to poor glycemic control
are treatment side effects, complex treatment
regimens, needle anxiety, poor patient
education, and the absence of an adequate
patient care plan [53].
Timely treatment intensification combined
with good treatment adherence is important for
reducing the total health care system costs






Mean HbA1c (%) reduction from
baseline to study endpoint
Vildagliptin cohort (n = 384) 8.5 7.1 -1.35
Comparator cohort (n = 369) 8.2 7.6 -0.55
Fig. 1 Responder rates (per protocol population;
(P\0.001); success: treatment response without
tolerability ﬁndings (HbA1c reduction—0.3%, without any
tolerability issues: peripheral edema, conﬁrmedhypoglycemia,
interruption due to GI reactions, and signiﬁcant weight gain
[5%); failure: lack of treatment response and/or occurrence
of any of the tolerability issues. Patients who could not
be categorized as a success or failure (e.g., due to missing
HbA1c or body weight data at 12-month endpoint) were
considered non-evaluable. Non-evaluable patient data were
considered failures in calculation of the odds ratio for success)
(%) of Bulgarian patients achieved primary effectiveness
endpoint after 12 months of treatment by groups
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spent in diabetes area [54]. Non-adherence to
therapy is a common problem associated with
chronic diseases and one of the major barriers to
optimum glycemic control in patients with
T2DM, leading to poor treatment outcomes
and increased utilization of health care
resources [54]. Non-adherence to therapy is
often related to adverse effects associated with
the therapy [55]. The presented sub-analysis
regarding Bulgarian results from EDGE study
confirmed that vildagliptin could be used as
effective and well tolerated second-line therapy.
A significantly higher proportion of patients
treated with vildagliptin achieved the HbA1c
reduction of [0.3% without any tolerability
issues: peripheral edema, confirmed
hypoglycemic events, treatment interruption
due to GI reactions and significant weight gain
of [5%. This result is important, as it is
hypoglycemia, weight gain and other AEs that
lead to significant worsening of compliance and
therapy adherence [55].
Furthermore, comparing the results
regarding vildagliptin efficacy determined in
RCTs [56] and in routine clinical practice we
could conclude that the full power of treatment
with vildagliptin is retained in real-life
conditions in contrast to comparators with
special focus on SUs. In the comparator
cohort, approximately 90.8% of patients were
treated with combination therapy with












PEP decrease HbA1c[0.3 %, no
hypoglycemia, no weight gain, no
discontinuation for GI events, no
peripheral edema
280 (72.9%) 148 (40.1%) 4.0 ± 0.6 (2.96–5.46) 0.001
SEP HbA1c\7 % at EOS without proven
hypoglycemic events or weight gain C3 %
population and baseline HbA1c[7 %
116 (32.3%) 28 (8.4%) 5.2 ± 1.2 (3.35–8.17) 0.001
CI conﬁdence interval, EOS end of the study, GI gastrointestinal, HbA1c glycated hemoglobin, PEP primary effectiveness
endpoint, SEP secondary effectiveness endpoint
Fig. 2 Responder rates (per protocol population;
(P\0.001); success: treatment response without
tolerability ﬁndings (HbA1c \7%, without hypoglycemic
events or weight gain); patients who could not be categorized
as a success or failure (e.g., due to missing HbA1c or body
weight data at 12-month endpoint) were considered non-
evaluable. Non-evaluable patient data were considered
failures in calculation of the odds ratio for success) (%) of
Bulgarian patients achieved secondary effectiveness
endpoint after 12 months of treatment by groups
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metformin and SUs. The HbA1c reduction seen
in the comparator cohort could be evaluated as
a result of the addition of SUs and was lower
compared to the reduction seen in RCTs [40,
41]. A recently published analysis comparing
RCTs to real-life data revealed that the decrease
in HbA1c from baseline with SUs treatment is
smaller in real life than in RCTs, whereas the
reduction with vildagliptin is essentially the
same [57]. The authors admitted that the cause
of blunting of the HbA1c response to SUs in real
life is unclear. They explore a hypothesis that
the patient compliance with SUs therapy is
reduced due to a fear of hypoglycemia and
weight gain driven by defensive eating
commonly associated with SUs. This could
explain also the lack of aggressive dose up-
titration in observational studies in which strict
dosing regimen according to the study protocol
is not required in comparison to RCTs [57].
Some of the study limitations could be seen in
the conduct of the trial—patients were recruited
both in specialized centers and by physicians
working in routine care which impacted the
overall number of investigators and overall
results because of poor quality data and missing
data which needed to be excluded from the
effectiveness analyses. Safety events were likely
underreported as the detection and reporting of
AEs were based on the voluntary reporting
Table 7 Overall adverse events by primary system organ class and treatment cohort (ITT population)
Primary system organ class Vildagliptin (n5 384) Comparator (n5 369) Total (n5 753)
n (%) AEs (%) SAEs (%) AEs (%) SAEs (%) AEs (%) SAEs (%)
Gastrointestinal disorders 1 (7.7) 0 (0.0) 1 (14.3) 0 (0.0) 2 (10.0) 0 (0.0)
General disorders 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0) 1 (5.0) 1 (7.7)
Hepatobiliary disorders 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0) 1 (5.0) 1 (7.7)
Investigations 2 (15.4) 1 (11.1) 0 (0.0) 0 (0.0) 2 (10.0) 2 (15.4)
Metabolism and nutrition disorders 0 (0) 0 (0.0) 2 (28.6) 0 (0.0) 2 (10.0) 0 (0.0)
Neoplasms benign, malign 1 (7.7) 0 (0.0) 2 (28.6) 2 (50.0) 3 (15.0) 2 (15.4)
Nervous system disorders 2 (15.4) 2 (22.2) 1 (14.3) 1 (25.0) 3 (15.0) 3 (23.1)
Psychiatric disorders 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0) 1 (5.0) 1 (7.7)
Renal and urinary disorders 1 (7.7) 1 (11.1) 0 (0.0) 0 (0.0) 1 (5.0) 1 (7.7)
Skin and subcutaneous disorders 1 (7.7) 0 (0.0) 0 (0.0) 0 (0.0) 1 (5.0) 0 (0.0)
Cardiac disorders 2 (15.4) 2 (22.2) 1 (14.3) 1 (25.0) 3 (15.0) 3 (23.1)
Total 13 (100.0) 9 (100.0) 7 (100.0) 4 (100.0) 20 (100.0) 13 (100.0)
Data are meaning n (%)
Adverse events were coded according to MedDRA version 14.0 [58]
Primary system organ classes (SOC)s are presented alphabetically
A patient with multiple occurrences of an AE under one cohort is counted only once in the AE category
A patient with multiple AEs within a primary system organ class is counted only once in the total row for that cohort
Switches from vildagliptin/metformin ﬁxed dose to vildagliptin as add-on dual therapy to metformin and vice versa were not
counted as treatment change
Total also contains patients without initial dual therapy
AE adverse event, ITT intent to treat, SAE serious adverse event
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scheme which is the most widely used method to
identify AEs for new drugs in clinical practice.
The present study is a post hoc analysis and
shares all the limitations of secondary analysis
such as no adjustment of the results for major
potential confounders was not done (e.g., age,
sex, duration, baseline HbA1c, baseline BMI).
In conclusion, this study demonstrated that
in analogy to findings in the worldwide EDGE
study [26], vildagliptin is both efficacious and
safe when used as a second oral glucose-
lowering agent in Bulgarian cohort of type 2
diabetic patients. In real-life clinical practice in
Bulgaria, vildagliptin is a valid option to use in
combination with metformin or any other oral
glucose-lowering drug in patients with T2DM
who require combination therapy. Vildagliptin
also provides a greater HbA1c drop, less
hypoglycemic events and a higher proportion
of patients reaching target HbA1c without
hypoglycemia and weight gain compared to
other OADs add-on as second-line therapy.
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